- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
- 10-Q Quarterly report
- 10.5.2 EX-10.5.2 Forms of Restricted Stock Unit Award Grant Notice and Award Agreement Under the 2020 Equity Incentive Plan
- 10.37 EX-10.37 First Amendment to the Non-exclusive License Agreement Between Bio-rad Laboratories, Inc., and Biodesix, Inc., Dated May 24, 2021.
- 10.38 EX-10.38 Amendment No 2. to Asset Purchase Agreement and Plan of Reorganization
- 31.1 EX-31.1
- 31.2 EX-31.2
- 32.1 EX-32.1
- 32.2 EX-32.2
- Download Excel data file
- View Excel data file
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Biodesix, Inc. (the “Company”) on Form 10-Q for the period ending June 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
| (1) | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: August 10, 2021 |
| By: | /s/ Scott Hutton |
|
|
| Scott Hutton |
|
|
| Chief Executive Officer |